192 results about "Diagnostic marker" patented technology

The invention discloses application of a diagnostic marker in preparation of a rheumatoid arthritis diagnostic product and a diagnostic system, and relates to the technical field of rheumatoid arthritis diagnosis. And the diagnostic marker comprises KMT2B, KMT2C, IFITM3, ECHS1, LYMPH%, MONO%, PDW, Path.CAST, RDW and RDW%. The diagnosis marker provided by the invention has extremely high diagnosis efficiency and has a good application prospect in the field of diagnosis of rheumatoid arthritis.

A method of automatically diagnosing pneumonia in a patient includes obtaining values of two or more diagnostic parameters of the patient from a caregiver of the patient using an input / output interface device. The method includes applying, using a processor connected to an input / output interface, two or more diagnostic parameters to an electronic memory storing a plurality of pre-compiled pneumonia diagnostic models to identify an optimal diagnostic model for performing the diagnosis. The values of the two or more diagnostic markers are applied to the identified optimal diagnostic model to generate a diagnostic output. An input / output interface device is operated according to the diagnostic output to indicate to the caregiver the presence or absence of pneumonia in the patient. The caregiver may use the diagnostics to provide appropriate care for the patient. A pneumonia diagnostic model is from investigations of pneumonia-positive and non-pneumonia population of subjects.

The invention discloses a generalized pustular psoriasis diagnosis marker based on metabonomics and application of the generalized pustular psoriasis diagnosis marker. The diagnostic marker is prepared from one or more of the following 35 compounds: pyruvic acid, alpha-ketoisovaleric acid, 2-hydroxybutyric acid, 3-hydroxybutyric acid, methane thiophosphoric acid, proline, uracil, tranexamic acid, 4-aminobutyric acid, threonine, scopoletin, dodecanol, N-methyl-L-leucine, L-cysteine-glycine and L-kynurenine. The feed additive is prepared from the following raw materials: 3-hydroxybenzoic acid, allantoin, delta-tocopherol, xylofuranose, glucose-1-phosphoric acid, pyrophosphate, taurine, L-asparagine, phthalic acid, 4-(dimethylamino) azobenzene, 5-tert-butyl-1h-indole-2, 3-dione, quinic acid, glucose, histidine, lysine, palmitic acid, 7-methylguanine, oleic acid and whale acid. The marker can be used for accurately distinguishing patients with generalized pustular psoriasis from healthy people.

The present application relates to the technical field of diagnostic markers, in particular to a marker combination and its application in diagnosing active tuberculosis and distinguishing between latent tuberculosis infection and active tuberculosis. The lectin combination provided by the present application can be used as a marker for ATB diagnosis and distinguishing between LTBI and ATB, and has high specificity and sensitivity. The lectin combination provided by the present application in combination with detection of specific antibodies of mycobacterium tuberculosis antigens can further improve the diagnostic effect. The marker and its detection products provided by the present application have good application potential in ATB diagnosis and distinguishing between LTBI and ATB, and are expected to overcome the limitations of existing diagnostic techniques, improve the diagnostic accuracy and sensitivity of tuberculosis, and provide new ideas and technical means for early detection, precise treatment and effective prevention and control of tuberculosis.

The application belongs to the technical field of biotechnology, and particularly relates to a colorectal cancer high liver metastasis cell line and a preparation method and application thereof. The cell line was preserved in the China Center for Type Culture Collection on January 14, 2026, and the preservation number is CCTCC NO: C202618. The cell line is derived from a mouse colorectal cancer cell line MC38, and is constructed by lentivirus transfection to express luciferase stably, and is obtained by continuously performing at least five rounds of liver metastasis tumor orthotopic iteration screening in C57BL / 6 mice through rectal submucosal injection. The MC38-P06 cell line provided by the application has a significantly enhanced liver metastasis ability, a shorter MC38-P01 model time, a higher liver tumor load, and a shorter mouse survival period, and can be used for screening and evaluating anti-liver metastasis drugs, researching liver microenvironment regulation mechanisms, and identifying liver metastasis related diagnostic markers.

The invention discloses a diagnostic marker for ANCA (Angiovasculitis) related vasculitis. It is found for the first time that the CD19 + CD38 + CD27-CD24 + cell can be used as the diagnosis marker of ANCA related vasculitis, and the diagnosis efficiency is high; in addition, it is found that the CD19 + CD38 + CD27-CD24 + cells can remarkably distinguish ANCA related vasculitis and membranous nephropathy or ANCA related vasculitis and lupus nephritis, a new direction is provided for diagnosis and subsequent treatment of ANCA related vasculitis, and the application has wide application prospects clinically.

The invention discloses a colon cancer diagnostic marker screening method and system based on transcriptome data, and belongs to the technical field of biological information, and the method comprises the steps of data preparation, pathological hierarchical modeling, diagnostic marker screening and screening report generation. According to the method, pathological hierarchical modeling based on dynamic discrimination and double-layer feature fusion is adopted, on the basis of comprehensively considering gene expression and pathological morphology information, pathological subtypes of colon cancer samples are adaptively recognized, stable and representative subtype features are obtained, and therefore the accuracy and biological representativeness of diagnostic marker screening are improved; diagnostic marker screening based on pathological subtype difference analysis is adopted, and on the premise of considering pathological subtype characteristics, a stable and reliable diagnostic marker set with remarkable expression difference is screened in a targeted manner, so that the biological representativeness, screening robustness and diagnostic specificity of markers are improved.

The invention belongs to the technical field of gene editing and disease model construction, and particularly relates to a construction method and application of a Wilson disease animal model. Aiming at a large fragment deletion mutation type which exists clinically in Wilson disease but lacks a corresponding animal model, a CRISPR / Cas9 gene editing technology is utilized, a pair of sgRNAs is specifically designed, an eighth exon region of a mouse Atp7b gene is precisely cut and deleted, and a WD mouse model with deletion mutation (c.2333340delGACGGTGG) of eight basic groups of the eighth exon of the Atp7b gene is successfully constructed. The method can be used for research on pathogenesis of WD, screening of novel diagnostic markers and evaluation of curative effect of therapeutic drugs, is particularly suitable for preclinical evaluation of gene therapy strategies and development of adjuvant therapeutic drugs of targeted NLRP3 inflammasomes, and has great scientific research value and clinical transformation prospect.

The present study of the regulatory T phenotype of Sézary cells led to the discovery of the expression of GARP (LRRC32) by Sézary cells. GARP has also been shown to be overexpressed in samples from patients with acute lymphoblastic leukemia. GARP therefore appears as a diagnostic marker, for monitoring T-cell malignancies, and as a therapeutic target. Accordingly, the present invention relates to methods for the diagnosis and treatment of T-cell malignancies.

This invention relates to the field of molecular diagnostics, specifically providing a diagnostic kit for the combined detection of DLBCL based on plasma exosomal miRNAs. This invention provides two or more peripheral blood exosomes used as diagnostic biomarkers for diffuse large B-cell lymphoma (DLBCL). Based on these DLBCL diagnostic biomarkers, this invention also provides a non-invasive, highly reproducible, and highly specific plasma exosomal miRNA diagnostic kit for the early diagnosis and follow-up monitoring of DLBCL. The plasma exosomal miRNA diagnostic kit provided by this invention is of great significance in the early diagnosis, genotyping, relapse monitoring, and efficacy evaluation of DLBCL.

The invention discloses a generalized pustular psoriasis diagnosis marker based on metabonomics and application of the generalized pustular psoriasis diagnosis marker. The diagnostic marker is prepared from one or more of the following 35 compounds: pyruvic acid, alpha-ketoisovaleric acid, 2-hydroxybutyric acid, 3-hydroxybutyric acid, methane thiophosphoric acid, proline, uracil, tranexamic acid, 4-aminobutyric acid, threonine, scopoletin, dodecanol, N-methyl-L-leucine, L-cysteine-glycine and L-kynurenine. The feed additive is prepared from the following raw materials: 3-hydroxybenzoic acid, allantoin, delta-tocopherol, xylofuranose, glucose-1-phosphoric acid, pyrophosphate, taurine, L-asparagine, phthalic acid, 4-(dimethylamino) azobenzene, 5-tert-butyl-1h-indole-2, 3-dione, quinic acid, glucose, histidine, lysine, palmitic acid, 7-methylguanine, oleic acid and whale acid. The marker can be used for accurately distinguishing patients with generalized pustular psoriasis from healthy people.

The invention relates to the technical field of biological medicine, in particular to application of MSR1 in preparation of medicine for preventing and / or treating HLH / MAS. The invention provides a novel HLH / MAS specific diagnosis marker, and solves the problem of insufficient specificity of the existing diagnosis method. The invention discloses the key effect of the MSR1-mtROS-NLRP3 axis in the HLH / MAS attack, and provides a new target spot for treatment. The sMSR1 detection method is simple and easy to implement and suitable for clinical popularization and use, and a new tool is provided for precise diagnosis and individualized treatment of HLH / MAS.

Provided are a small protein UFD1s and use thereof in the prevention, treatment, and diagnosis of non-alcoholic steatohepatitis. The provided small protein UFD1s can regulate energy metabolism and combat cell stress, and UFD1s can be used as an auxiliary diagnostic marker for non-alcoholic steatohepatitis (NASH). Meanwhile, the deletion or low expression level of UFD1s is related to the development and progression of NASH. By expressing UFD1s in vivo by means of a constructed expression vector and a method, its effect in preventing and / or treating NASH can be exerted, thereby providing a new idea for the prevention and / or treatment of NASH.

The application provides application of dimethyl carbonate as a chronic obstructive pulmonary disease diagnostic marker and belongs to the technical field of biomedical detection. The application first finds that the detection rate of dimethyl carbonate in exhaled air is significantly related to chronic obstructive pulmonary disease, and the detection rate of dimethyl carbonate in exhaled air of a chronic obstructive pulmonary disease patient is significantly higher than that of a healthy person. The ROC curve analysis result shows that dimethyl carbonate has extremely high specificity as a biomarker for diagnosing chronic obstructive pulmonary disease, and therefore can be used as a detection target for the diagnosis of chronic obstructive pulmonary disease patients, and has good practical application value.

The application relates to the field of biological medicine, and discloses application of folic acid in prevention, diagnosis and treatment of genetic, infectious or allergic diseases. The application finds that the folic acid can achieve the prevention and treatment effects on the genetic, infectious or allergic diseases by improving inflammation, regulating iron ion metabolism, correcting intestinal flora disorder, reducing liver / intestinal tissue damage, inhibiting expression of inflammatory factors and promoting expression of Nox2. Meanwhile, the application provides application of one or more of the folic acid, S100a8, S100a9, Nox2 and IFN-gamma as a diagnostic or auxiliary diagnostic marker of biliary atresia. Meanwhile, the application provides the folic acid or a derivative thereof, which is prepared into food, a nutritional preparation or a medicine and applied to children or adults, so as to achieve the purposes of preventing and treating biliary atresia, cholangitis, jaundice, infectious diseases, intestinal diseases and diseases caused by abnormal folic acid metabolism.

The application relates to the field of biological medicine, and particularly discloses Creld2 as a biomarker of atherosclerosis. For the first time, the Creld2 level of mouse models of obesity, diabetes, hyperlipidemia and atherosclerosis is detected, and it is found that the serum Creld2 level is greatly increased only when atherosclerosis occurs. The increase of the Creld2 level is related to the development process of atherosclerosis, and with the aggravation of atherosclerotic plaques, the serum Creld2 level is further increased. The serum Creld2 level of the atherosclerosis model group is greatly increased compared with the normal control group, and the Creld2 level ranges of the two groups do not overlap, so that the Creld2 is taken as the biomarker of atherosclerosis and has high diagnostic efficiency, can be used as an early blood diagnostic marker of atherosclerosis, is beneficial to low-cost, large-scale screening and monitoring, can be used for early diagnosis and treatment of atherosclerosis, and improves the life quality of patients.

The invention relates to a set of diagnostic markers comprising glutamic acid, glutamine, glycine, tryptophan, proline, threonine, citrulline, aspartic acid, and asparagine, for use in diagnosing breast cancer, and to an in vitro method for diagnosing breast cancer.

A diagnosis marker for pulmonary tuberculosis infection and a diagnosis kit thereof belong to the technical field of pulmonary tuberculosis diagnosis and treatment.The marker for detecting pulmonary tuberculosis provided by the present application is a LINC01148 gene, and the LINC01148 gene can be detected by primers to effectively diagnose whether a patient has pulmonary tuberculosis or not; the transcript sequence of the LINC01148 gene is SEQ ID NO.1, and the primer sequences of the LINC01148 gene are SEQ ID NO.2 and SEQ ID NO.3.Meanwhile, it is found that inhibiting the expression of the LINC01148 gene can effectively inhibit the activity of tubercle bacillus in macrophages, so the siRNA of the LINC01148 gene can be used for treating pulmonary tuberculosis.

The invention provides a plateau low-pressure and low-oxygen stress diagnostic marker and application thereof, and discloses a microRNA marker miR-874-3p which can be used for diagnosing low-pressure and low-oxygen stress and related diseases caused by sudden entry into plateau. The invention also provides application of the reagent for detecting the expression level of the miR-874-3p in preparation of a product for diagnosing diseases related to low-pressure and low-oxygen stress, wherein the low-pressure and low-oxygen stress is caused by sudden entry into the plateau.

The application provides a novel diagnostic marker for neuroendocrine prostate cancer and application thereof, and relates to the technical field of genetic engineering. The novel diagnostic marker is PCSK1N and / or C4orf48. The application overcomes the defects of the prior art, verifies the high expression of PCSK1N and / or C4orf48 in neuroendocrine prostate cancer, and based on this, the PCSK1N and / or C4orf48 can be used as a novel diagnostic marker for neuroendocrine prostate cancer.

The application provides a use of a substance for detecting SLAMF8 in the preparation of a product for screening and diagnosing prostate cancer and a detection kit, and relates to the technical field of biotechnology. The application finds that SLAMF8 can be used as a diagnostic marker of prostate cancer, and a kit using a primer probe group including a primer pair with a nucleotide sequence as shown in SEQ ID NO. 2 and 3; and a probe with a nucleotide sequence as shown in SEQ ID NO. 4 can efficiently diagnose prostate cancer.

The invention discloses a diagnosis marker for diabetes complicated with atrial fibrillation and application of the diagnosis marker, and relates to the technical field of biological medicine. The diagnostic marker is hematopoietic cell kinase (HCK). The invention finds that HCK can effectively predict the occurrence risk of diabetes mellitus combined with atrial fibrillation and provide an effective treatment target for diabetes mellitus combined with atrial fibrillation. The invention verifies that the knock-down HCK can effectively inhibit AGEs-induced HL-1 cell CaMKII phosphorylation, myocardial fibrosis, mitochondrial membrane potential damage and ROS generation, and alleviates the inhibition effect on AMPK / mTOR signal channel activation, thereby reducing the atrial fibrillation susceptibility. The invention also proves that the risk (AUC is 0.853) of the diabetic with atrial fibrillation can be accurately identified by detecting the HCK level in the plasma. The invention provides a new medical approach for early risk assessment and targeted intervention of diabetes mellitus combined with atrial fibrillation.

The invention discloses an application of TMEM106A as a target spot in preparation of a diagnostic kit and a targeted therapeutic drug. Relates to the technical field of immunodiagnosis. Specific applications are provided. The invention discloses a key effect of TMEM106A in podocyte injury related to preeclampsia. TMEM106A is significantly down-regulated in urine of a PE patient, is closely related to podocyte injury and inflammatory response, and can be used as an early noninvasive diagnostic marker; meanwhile, the targeted podocyte up-regulation TMEM106A has remarkable anti-inflammatory and kidney protection effects, and a theoretical basis and practical feasibility are provided for targeted therapy of PE-related podocyte injury. The invention provides a new way for early precise diagnosis and intervention strategy of PE, and has wide clinical application prospect.

The invention discloses a cell-penetrating peptide CPP137 as well as a compound, a composition and application thereof, and belongs to the technical field of polypeptides. According to the application, a cell-penetrating peptide CPP137 with immune cell selectivity is screened out from a plague bacillus sORF library. The polypeptide not only can be efficiently internalized by THP-1 (M0 type) mononuclear cells, but also can specifically target two key antigen presenting cells, namely primary macrophages and dendritic cells (DC), in a complex human whole blood physiological environment, but is not obviously combined with other blood cell types. Therefore, the cell-penetrating peptide CPP137 is a targeted delivery carrier with great potential, can be used for specifically delivering a therapeutic load to myeloid immune cells, and is used for treating intracellular infection and immune-related diseases or used as a vaccine development platform. Meanwhile, CPP137 can also be used as a specific diagnostic marker or an imaging probe for detecting or tracing pathological states related to macrophages / DC.

The invention discloses an application of DARS2 as a diagnostic marker of a Dravot syndrome. According to the application disclosed by the invention, the level of the Dars2 in the brain of a rat with the Dars2 is remarkably increased, and the level of the Dars2 in blood after epileptic seizure of the rat with the DS induced by the LPS is remarkably increased. The reagent for detecting the expression level of the DARS2 in the sample can be used for preparing a product for early diagnosis of the Dravet syndrome and disease monitoring.

The invention relates to new chemical compounds and combinations of chemical compounds, for medical use, more specifically for cancer diagnosis, in particular for the detection of activity specific for pancreatic cancer and in the diagnosis of pancreatic cancer. The invention relates also to an in vitro method for the detection of enzymatic activity present in an individual's body fluid sample, using such a compound or combination. The invention further relates to an in vitro method for the diagnosis of pancreatic cancer, using such a compound or combination, a kit comprising such a compound or combination, and the use of such a compound or combination for detecting enzymatic activity specific for pancreatic cancer and the use of such a compound or combination for the diagnosis of pancreatic cancer. The invention relates furthermore to such a compound or combination of compounds for use as a diagnostic marker for pancreatic cancer, and a method for the treatment of pancreatic cancer comprising the step of carrying out the method for the diagnosis of pancreatic cancer as defined above using such a compound or combination.

The application discloses a cervical cancer circRNA marker and application thereof, and belongs to the technical field of biology. The inventors have found that the expression level of circular RNA hsa_circ_0002828 in the plasma of a cervical cancer patient is significantly lower than that in the plasma of a healthy person, thereby indicating that hsa_circ_0002828 can be used as a diagnostic marker for cervical cancer and for predicting the occurrence of cervical cancer. Meanwhile, after overexpression of hsa_circ_0002828, the proliferation ability and invasion ability of cervical cancer cells can be significantly inhibited, and tumor cell apoptosis can be strongly induced. These results show that hsa_circ_0002828 can be used as a tumor diagnosis marker and a potential target for tumor treatment, and is expected to be applied to the diagnosis and treatment of cervical cancer.

The invention relates to a computer-implemented method for detecting oesophageal squamous cell dysplasia (OSCD) or oesophageal squamous cell cancer (OSCC) in a cell sample from a subject. This invention also relates to a computer-implemented method for generating a trained model to detect OSCD or OSCC. This invention also relates to a computer-readable storage medium or a computer program comprising instructions which when executed by a computer, are capable of causing the computer to perform the method. This invention also relates to a kit comprising the computer program or computer-readable storage medium and a non-endoscopic cell collection device. The invention also relates to an apparatus for performing the method. The invention further relates to the use of genome wide instability scores (GWIS) as a diagnostic marker for cancer, wherein GWIS is a measure of the CNV across a plurality of autosomal arms in a cell sample from a subject.

The invention provides a polypeptide for detecting an ACPA negative rheumatoid arthritis diagnosis marker and application of the polypeptide. The rheumatoid arthritis diagnostic marker is an anti-Pentaxin associated protein 3 antibody, and the amino acid sequence of the polypeptide, namely PTX3, is shown as SEQ ID NO. 4. The invention relates to an application of PTX3 in preparation of a reagent for diagnosing ACPA-negative rheumatoid arthritis. By detecting the rheumatoid arthritis diagnostic marker, the kit can be effectively used for detecting the rheumatoid arthritis, the detection rate is increased, and a basis is provided for preventing and treating the rheumatoid arthritis as soon as possible.